Natural Product: NPC158854
Natural Product ID:   | NPC158854 |
Common Name:   | Meperidine |
IUPAC Name:   | ethyl 1-methyl-4-phenylpiperidine-4-carboxylate |
Synonyms:   | Meperidine; Pethidine |
Molecular Formula:   | C15H21NO2 |
Standard InCHIKey:   | XADCESSVHJOZHK-UHFFFAOYSA-N |
Standard InCHI:   | InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3 |
Canonical SMILES:   | CCOC(=O)C1(CCN(CC1)C)c1ccccc1 |
First Find Year:   | |
Max Developmental Stage:   | |
Synthetic Gene Cluster:   |
; |
  Species Source
Organism ID |
Organism Name |
Taxonomy Level |
Family |
SuperKingdom |
Isolation Part |
Collection Location |
Collection Time |
Reference |
NPO17922 |
Fritiliariae irrhosae bulbus |
NA |
NA |
NA |
|
|
|
TCMSP* |
  Biological Activity
Activity Type |
# Activity |
EC50 |
2 |
ED50 |
8 |
IC50 |
11 |
Ki |
4 |
Others |
13 |
Activity Type |
# Activity |
Individual Protein |
12 |
Organism |
17 |
Protein Family |
9 |
Target ID |
Target Type |
Target Name |
Target Organism |
Activity Type |
Activity Relation |
Value |
Unit |
Reference |
NPT1073 |
Individual Protein |
Dopamine transporter |
Rattus norvegicus |
Ki |
= |
17800 |
nM |
10612583 |
NPT1072 |
Individual Protein |
Serotonin transporter |
Rattus norvegicus |
Ki |
= |
412 |
nM |
10612583 |
NPT145 |
Individual Protein |
Mu opioid receptor |
Homo sapiens |
IC50 |
= |
315 |
nM |
11585443 |
NPT272 |
Individual Protein |
Kappa opioid receptor |
Homo sapiens |
IC50 |
= |
2370 |
nM |
11585443 |
NPT271 |
Individual Protein |
Delta opioid receptor |
Homo sapiens |
IC50 |
> |
10000 |
nM |
11585443 |
NPT3590 |
Protein Family |
Opioid receptor |
Rattus norvegicus |
IC50 |
= |
6000 |
|
3007760 |
NPT3590 |
Protein Family |
Opioid receptor |
Rattus norvegicus |
IC50 |
= |
80000 |
|
3007760 |
NPT3590 |
Protein Family |
Opioid receptor |
Rattus norvegicus |
Ratio |
= |
13.3 |
|
3007760 |
NPT4389 |
Protein Family |
Opioid receptors; mu/kappa/delta |
Homo sapiens |
IC50 |
= |
500 |
nM |
6106064 |
NPT4389 |
Protein Family |
Opioid receptors; mu/kappa/delta |
Homo sapiens |
IC50 |
= |
40000 |
nM |
6106064 |
NPT4389 |
Protein Family |
Opioid receptors; mu/kappa/delta |
Homo sapiens |
Ratio |
= |
80 |
|
6106064 |
NPT32 |
Organism |
Mus musculus |
Mus musculus |
ED50 |
= |
1.3 |
mg/kg |
6283082 |
NPT32 |
Organism |
Mus musculus |
Mus musculus |
ED50 |
= |
25 |
umol/kg |
2845084 |
NPT32 |
Organism |
Mus musculus |
Mus musculus |
ED50 |
= |
4.1 |
mg/kg |
4068011 |
NPT29 |
Organism |
Rattus norvegicus |
Rattus norvegicus |
ED50 |
= |
6.15 |
mg/kg |
4068011 |
NPT2863 |
Protein Family |
Opioid receptor |
Mus musculus |
IC50 |
= |
500 |
nM |
8410989 |
NPT1074 |
Individual Protein |
Mu opioid receptor |
Cavia porcellus |
Ki |
= |
451 |
nM |
9873439 |
NPT1075 |
Individual Protein |
Kappa opioid receptor |
Cavia porcellus |
Ki |
> |
100000 |
nM |
9873439 |
NPT98 |
Individual Protein |
HERG |
Homo sapiens |
IC50 |
= |
323.59 |
nM |
15911273 |
NPT145 |
Individual Protein |
Mu opioid receptor |
Homo sapiens |
EC50 |
= |
9400 |
nM |
19168350 |
NPT98 |
Individual Protein |
HERG |
Homo sapiens |
IC50 |
= |
75857.76 |
nM |
18262683 |
NPT98 |
Individual Protein |
HERG |
Homo sapiens |
IC50 |
= |
74131.02 |
nM |
21185626 |
NPT902 |
Individual Protein |
UDP-glucuronosyltransferase 1A4 |
Homo sapiens |
Activity |
= |
36 |
pm/min/mg |
10836148 |
NPT32 |
Organism |
Mus musculus |
Mus musculus |
ED50 |
= |
4.7 |
mg/kg |
109618 |
NPT3590 |
Protein Family |
Opioid receptor |
Rattus norvegicus |
EC50 |
= |
700 |
nM |
109618 |
NPT29 |
Organism |
Rattus norvegicus |
Rattus norvegicus |
Activity |
= |
1.2 |
mA |
853506 |
NPT32 |
Organism |
Mus musculus |
Mus musculus |
Activity |
= |
50 |
% |
853506 |
NPT32 |
Organism |
Mus musculus |
Mus musculus |
Activity |
= |
70 |
% |
853506 |
NPT1016 |
Organism |
Canis familiaris |
Canis lupus familiaris |
Activity |
= |
150 |
% |
853506 |
NPT29 |
Organism |
Rattus norvegicus |
Rattus norvegicus |
ED50 |
= |
10 |
mg/kg |
853506 |
NPT32 |
Organism |
Mus musculus |
Mus musculus |
Activity |
= |
296 |
% |
628000 |
NPT32 |
Organism |
Mus musculus |
Mus musculus |
Activity |
= |
231 |
% |
628000 |
NPT32 |
Organism |
Mus musculus |
Mus musculus |
Activity |
= |
194 |
% |
628000 |
NPT32 |
Organism |
Mus musculus |
Mus musculus |
Activity |
= |
160 |
% |
628000 |
NPT29 |
Organism |
Rattus norvegicus |
Rattus norvegicus |
AD50 |
= |
19 |
mg/kg |
31481 |
NPT29 |
Organism |
Rattus norvegicus |
Rattus norvegicus |
AD50 |
= |
25 |
mg/kg |
31481 |
NPT3590 |
Protein Family |
Opioid receptor |
Rattus norvegicus |
ED50 |
= |
700 |
nM |
199728 |
NPT32 |
Organism |
Mus musculus |
Mus musculus |
ED50 |
= |
4.5 |
mg/kg |
814236 |
  Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC158854 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 71 |
0.1-0.2 | 527 |
0.2-0.3 | 1696 |
0.3-0.4 | 6092 |
0.4-0.5 | 15786 |
0.5-0.6 | 5889 |
0.6-0.7 | 788 |
0.7-0.8 | 35 |
0.8-0.85 | 5 |
0.85-0.9 | 0 |
0.9-0.95 | 0 |
0.95-1 | 0 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC158854 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 83 |
0.1-0.2 | 393 |
0.2-0.3 | 860 |
0.3-0.4 | 1813 |
0.4-0.5 | 3245 |
0.5-0.6 | 1998 |
0.6-0.7 | 579 |
0.7-0.8 | 155 |
0.8-0.85 | 25 |
0.85-0.9 | 8 |
0.9-0.95 | 0 |
0.95-1 | 2 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
1.0 |
High Similarity |
NPD1756 |
Approved |
1.0 |
High Similarity |
NPD1752 |
Approved |
0.8879 |
High Similarity |
NPD3646 |
Clinical (unspecified phase) |
0.886 |
High Similarity |
NPD7437 |
Approved |
0.886 |
High Similarity |
NPD7436 |
Approved |
0.8829 |
High Similarity |
NPD4576 |
Approved |
0.8829 |
High Similarity |
NPD4574 |
Approved |
0.8807 |
High Similarity |
NPD2607 |
Approved |
0.8532 |
High Similarity |
NPD4234 |
Approved |
0.8532 |
High Similarity |
NPD4233 |
Approved |
0.8426 |
Intermediate Similarity |
NPD5705 |
Approved |
0.8426 |
Intermediate Similarity |
NPD5706 |
Approved |
0.8426 |
Intermediate Similarity |
NPD5704 |
Approved |
0.8393 |
Intermediate Similarity |
NPD1373 |
Approved |
0.8393 |
Intermediate Similarity |
NPD1374 |
Approved |
0.8393 |
Intermediate Similarity |
NPD1371 |
Approved |
0.8393 |
Intermediate Similarity |
NPD1370 |
Approved |
0.8319 |
Intermediate Similarity |
NPD4766 |
Approved |
0.8276 |
Intermediate Similarity |
NPD6993 |
Approved |
0.8276 |
Intermediate Similarity |
NPD6994 |
Approved |
0.822 |
Intermediate Similarity |
NPD2610 |
Approved |
0.822 |
Intermediate Similarity |
NPD3131 |
Approved |
0.822 |
Intermediate Similarity |
NPD4215 |
Approved |
0.822 |
Intermediate Similarity |
NPD2608 |
Approved |
0.822 |
Intermediate Similarity |
NPD4217 |
Approved |
0.822 |
Intermediate Similarity |
NPD2611 |
Approved |
0.822 |
Intermediate Similarity |
NPD4216 |
Approved |
0.822 |
Intermediate Similarity |
NPD2612 |
Approved |
0.822 |
Intermediate Similarity |
NPD2609 |
Approved |
0.822 |
Intermediate Similarity |
NPD3132 |
Approved |
0.822 |
Intermediate Similarity |
NPD4218 |
Approved |
0.808 |
Intermediate Similarity |
NPD5182 |
Approved |
0.808 |
Intermediate Similarity |
NPD5184 |
Approved |
0.808 |
Intermediate Similarity |
NPD5185 |
Approved |
0.8017 |
Intermediate Similarity |
NPD5667 |
Approved |
0.7965 |
Intermediate Similarity |
NPD2201 |
Approved |
0.7951 |
Intermediate Similarity |
NPD6563 |
Approved |
0.7951 |
Intermediate Similarity |
NPD6565 |
Approved |
0.7951 |
Intermediate Similarity |
NPD6564 |
Approved |
0.7903 |
Intermediate Similarity |
NPD4620 |
Approved |
0.7903 |
Intermediate Similarity |
NPD4617 |
Approved |
0.7903 |
Intermediate Similarity |
NPD5203 |
Approved |
0.7903 |
Intermediate Similarity |
NPD5201 |
Approved |
0.789 |
Intermediate Similarity |
NPD6024 |
Approved |
0.789 |
Intermediate Similarity |
NPD4803 |
Discontinued |
0.789 |
Intermediate Similarity |
NPD6027 |
Approved |
0.783 |
Intermediate Similarity |
NPD4094 |
Approved |
0.7797 |
Intermediate Similarity |
NPD2116 |
Approved |
0.7797 |
Intermediate Similarity |
NPD2115 |
Approved |
0.7797 |
Intermediate Similarity |
NPD2117 |
Pre-registration |
0.776 |
Intermediate Similarity |
NPD5202 |
Clinical (unspecified phase) |
0.776 |
Intermediate Similarity |
NPD2613 |
Approved |
0.7759 |
Intermediate Similarity |
NPD2650 |
Approved |
0.7759 |
Intermediate Similarity |
NPD2652 |
Approved |
0.7757 |
Intermediate Similarity |
NPD1989 |
Approved |
0.7731 |
Intermediate Similarity |
NPD2994 |
Approved |
0.7717 |
Intermediate Similarity |
NPD7714 |
Approved |
0.7717 |
Intermediate Similarity |
NPD7715 |
Approved |
0.7692 |
Intermediate Similarity |
NPD3648 |
Clinical (unspecified phase) |
0.7685 |
Intermediate Similarity |
NPD4655 |
Approved |
0.7685 |
Intermediate Similarity |
NPD4657 |
Approved |
0.7667 |
Intermediate Similarity |
NPD3031 |
Approved |
0.7667 |
Intermediate Similarity |
NPD3032 |
Approved |
0.7667 |
Intermediate Similarity |
NPD3030 |
Approved |
0.7661 |
Intermediate Similarity |
NPD2625 |
Approved |
0.7661 |
Intermediate Similarity |
NPD2627 |
Approved |
0.7661 |
Intermediate Similarity |
NPD2159 |
Approved |
0.7661 |
Intermediate Similarity |
NPD2628 |
Approved |
0.7661 |
Intermediate Similarity |
NPD2160 |
Approved |
0.7661 |
Intermediate Similarity |
NPD2626 |
Approved |
0.7656 |
Intermediate Similarity |
NPD5121 |
Approved |
0.7656 |
Intermediate Similarity |
NPD5120 |
Approved |
0.7656 |
Intermediate Similarity |
NPD5119 |
Approved |
0.7647 |
Intermediate Similarity |
NPD5990 |
Approved |
0.7647 |
Intermediate Similarity |
NPD5991 |
Approved |
0.7607 |
Intermediate Similarity |
NPD3598 |
Phase 3 |
0.7603 |
Intermediate Similarity |
NPD5306 |
Approved |
0.7603 |
Intermediate Similarity |
NPD5305 |
Approved |
0.7583 |
Intermediate Similarity |
NPD6345 |
Approved |
0.7583 |
Intermediate Similarity |
NPD6343 |
Approved |
0.7578 |
Intermediate Similarity |
NPD3087 |
Approved |
0.7578 |
Intermediate Similarity |
NPD3088 |
Approved |
0.7578 |
Intermediate Similarity |
NPD2566 |
Approved |
0.7578 |
Intermediate Similarity |
NPD7713 |
Phase 3 |
0.7578 |
Intermediate Similarity |
NPD2570 |
Approved |
0.7578 |
Intermediate Similarity |
NPD4746 |
Phase 3 |
0.7578 |
Intermediate Similarity |
NPD2574 |
Discontinued |
0.7578 |
Intermediate Similarity |
NPD2573 |
Approved |
0.7578 |
Intermediate Similarity |
NPD3615 |
Approved |
0.7578 |
Intermediate Similarity |
NPD4745 |
Approved |
0.7578 |
Intermediate Similarity |
NPD3089 |
Approved |
0.7578 |
Intermediate Similarity |
NPD2571 |
Approved |
0.7578 |
Intermediate Similarity |
NPD3616 |
Approved |
0.7578 |
Intermediate Similarity |
NPD3090 |
Approved |
0.7578 |
Intermediate Similarity |
NPD2572 |
Clinical (unspecified phase) |
0.7578 |
Intermediate Similarity |
NPD3614 |
Approved |
0.7576 |
Intermediate Similarity |
NPD7702 |
Clinical (unspecified phase) |
0.7565 |
Intermediate Similarity |
NPD5235 |
Approved |
0.7565 |
Intermediate Similarity |
NPD5237 |
Approved |
0.7565 |
Intermediate Similarity |
NPD5236 |
Approved |
0.7565 |
Intermediate Similarity |
NPD5240 |
Approved |
0.7565 |
Intermediate Similarity |
NPD5239 |
Approved |
0.7541 |
Intermediate Similarity |
NPD2946 |
Phase 2 |
0.7541 |
Intermediate Similarity |
NPD4106 |
Approved |
0.7541 |
Intermediate Similarity |
NPD4136 |
Approved |
0.7541 |
Intermediate Similarity |
NPD4135 |
Approved |
0.75 |
Intermediate Similarity |
NPD1087 |
Approved |
0.75 |
Intermediate Similarity |
NPD1755 |
Approved |
0.748 |
Intermediate Similarity |
NPD4807 |
Approved |
0.748 |
Intermediate Similarity |
NPD4806 |
Approved |
0.7477 |
Intermediate Similarity |
NPD1088 |
Approved |
0.7462 |
Intermediate Similarity |
NPD4685 |
Phase 3 |
0.7462 |
Intermediate Similarity |
NPD4686 |
Approved |
0.7462 |
Intermediate Similarity |
NPD4684 |
Phase 3 |
0.7455 |
Intermediate Similarity |
NPD253 |
Approved |
0.7455 |
Intermediate Similarity |
NPD4117 |
Approved |
0.7453 |
Intermediate Similarity |
NPD3672 |
Approved |
0.7453 |
Intermediate Similarity |
NPD3673 |
Approved |
0.7411 |
Intermediate Similarity |
NPD4719 |
Phase 2 |
0.7402 |
Intermediate Similarity |
NPD5204 |
Approved |
0.7387 |
Intermediate Similarity |
NPD742 |
Approved |
0.7385 |
Intermediate Similarity |
NPD6311 |
Approved |
0.7385 |
Intermediate Similarity |
NPD6310 |
Approved |
0.7385 |
Intermediate Similarity |
NPD6309 |
Approved |
0.7377 |
Intermediate Similarity |
NPD4105 |
Approved |
0.7377 |
Intermediate Similarity |
NPD4102 |
Approved |
0.7377 |
Intermediate Similarity |
NPD5981 |
Approved |
0.7364 |
Intermediate Similarity |
NPD4621 |
Approved |
0.7364 |
Intermediate Similarity |
NPD4619 |
Approved |
0.7355 |
Intermediate Similarity |
NPD6065 |
Approved |
0.7304 |
Intermediate Similarity |
NPD3524 |
Approved |
0.7304 |
Intermediate Similarity |
NPD3526 |
Approved |
0.7297 |
Intermediate Similarity |
NPD4813 |
Approved |
0.7297 |
Intermediate Similarity |
NPD4263 |
Approved |
0.729 |
Intermediate Similarity |
NPD1086 |
Approved |
0.729 |
Intermediate Similarity |
NPD1089 |
Approved |
0.729 |
Intermediate Similarity |
NPD1090 |
Approved |
0.7288 |
Intermediate Similarity |
NPD2124 |
Approved |
0.7266 |
Intermediate Similarity |
NPD3664 |
Approved |
0.7266 |
Intermediate Similarity |
NPD3662 |
Phase 3 |
0.7266 |
Intermediate Similarity |
NPD3663 |
Approved |
0.7266 |
Intermediate Similarity |
NPD3661 |
Approved |
0.7257 |
Intermediate Similarity |
NPD2171 |
Approved |
0.7257 |
Intermediate Similarity |
NPD4119 |
Approved |
0.7257 |
Intermediate Similarity |
NPD2193 |
Phase 2 |
0.7257 |
Intermediate Similarity |
NPD5716 |
Approved |
0.7257 |
Intermediate Similarity |
NPD2648 |
Phase 3 |
0.7228 |
Intermediate Similarity |
NPD9490 |
Approved |
0.7222 |
Intermediate Similarity |
NPD5158 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD5157 |
Phase 1 |
0.7222 |
Intermediate Similarity |
NPD5159 |
Phase 2 |
0.7218 |
Intermediate Similarity |
NPD2567 |
Approved |
0.7218 |
Intermediate Similarity |
NPD2569 |
Approved |
0.7217 |
Intermediate Similarity |
NPD1766 |
Approved |
0.7217 |
Intermediate Similarity |
NPD1765 |
Approved |
0.7217 |
Intermediate Similarity |
NPD1763 |
Approved |
0.7217 |
Intermediate Similarity |
NPD1767 |
Approved |
0.7217 |
Intermediate Similarity |
NPD1761 |
Approved |
0.7203 |
Intermediate Similarity |
NPD5927 |
Discontinued |
0.72 |
Intermediate Similarity |
NPD518 |
Clinical (unspecified phase) |
0.7196 |
Intermediate Similarity |
NPD800 |
Approved |
0.7193 |
Intermediate Similarity |
NPD3357 |
Discontinued |
0.7165 |
Intermediate Similarity |
NPD2199 |
Approved |
0.7165 |
Intermediate Similarity |
NPD2198 |
Approved |
0.7155 |
Intermediate Similarity |
NPD810 |
Approved |
0.7155 |
Intermediate Similarity |
NPD812 |
Approved |
0.7155 |
Intermediate Similarity |
NPD811 |
Approved |
0.7154 |
Intermediate Similarity |
NPD6039 |
Approved |
0.7143 |
Intermediate Similarity |
NPD466 |
Approved |
0.7115 |
Intermediate Similarity |
NPD9491 |
Approved |
0.7107 |
Intermediate Similarity |
NPD3867 |
Phase 2 |
0.7094 |
Intermediate Similarity |
NPD5979 |
Clinical (unspecified phase) |
0.7091 |
Intermediate Similarity |
NPD1563 |
Approved |
0.7069 |
Intermediate Similarity |
NPD5717 |
Approved |
0.7064 |
Intermediate Similarity |
NPD1239 |
Approved |
0.7063 |
Intermediate Similarity |
NPD3603 |
Phase 3 |
0.7059 |
Intermediate Similarity |
NPD3643 |
Approved |
0.7059 |
Intermediate Similarity |
NPD7611 |
Approved |
0.7059 |
Intermediate Similarity |
NPD3644 |
Approved |
0.7059 |
Intermediate Similarity |
NPD3642 |
Approved |
0.7043 |
Intermediate Similarity |
NPD4656 |
Approved |
0.7043 |
Intermediate Similarity |
NPD4658 |
Approved |
0.7029 |
Intermediate Similarity |
NPD2575 |
Approved |
0.7027 |
Intermediate Similarity |
NPD1693 |
Approved |
0.7018 |
Intermediate Similarity |
NPD2657 |
Approved |
0.7016 |
Intermediate Similarity |
NPD2617 |
Discontinued |
0.7016 |
Intermediate Similarity |
NPD998 |
Approved |
0.7 |
Intermediate Similarity |
NPD4573 |
Approved |
0.7 |
Intermediate Similarity |
NPD4571 |
Approved |
0.7 |
Intermediate Similarity |
NPD4572 |
Approved |
0.6992 |
Remote Similarity |
NPD5162 |
Approved |
0.6992 |
Remote Similarity |
NPD3373 |
Approved |
0.6983 |
Remote Similarity |
NPD2577 |
Clinical (unspecified phase) |
0.6961 |
Remote Similarity |
NPD227 |
Approved |
0.6961 |
Remote Similarity |
NPD225 |
Approved |
0.6949 |
Remote Similarity |
NPD4095 |
Clinical (unspecified phase) |
0.694 |
Remote Similarity |
NPD4618 |
Approved |
0.694 |
Remote Similarity |
NPD4622 |
Approved |
0.6934 |
Remote Similarity |
NPD4152 |
Approved |
0.693
|
Remote Similarity |
NPD2066 |
Phase 3 |